Tularik/Amgen
Tularik/Amgen is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Tularik/Amgen.
Tularik/Amgen is a company.
Key people at Tularik/Amgen.
Key people at Tularik/Amgen.
Tularik/Amgen refers to the acquisition of Tularik, a biotechnology company, by Amgen, a leading multinational biopharmaceutical firm. Amgen develops innovative therapies primarily for serious illnesses such as cancer, osteoporosis, and autoimmune diseases, serving patients worldwide. The acquisition of Tularik enhanced Amgen’s pipeline with promising drug candidates, particularly in areas like cancer and molecular biology, strengthening its position in biopharmaceutical innovation and expanding its research capabilities.
---
Amgen is a major biopharmaceutical company that develops and markets therapies for serious diseases, including osteoporosis, autoimmune disorders, and cancer. Its key products include Prolia, XGEVA, Enbrel, and Repatha, generating billions in annual revenue. Amgen serves patients, healthcare providers, and large drug wholesalers globally. The acquisition of Tularik added valuable drug candidates to Amgen’s pipeline, particularly in cancer therapeutics, supporting its mission to develop novel treatments that address unmet medical needs and improve patient outcomes.
---
Amgen was founded in 1980 in Thousand Oaks, California, originally named Applied Molecular Genetics, with a focus on recombinant DNA technology. It was backed by venture capitalists and led by George Rathmann as its first CEO. Over the decades, Amgen evolved into a global biopharmaceutical leader with a broad product portfolio and extensive clinical pipeline.
Tularik was a biotechnology company specializing in molecular biology and cancer drug discovery. Amgen acquired Tularik in 2004, a pivotal moment that brought five new drug candidates into Amgen’s development pipeline and established a strong presence in South San Francisco, a biotech hub. This acquisition marked a strategic expansion of Amgen’s research capabilities in oncology and molecular targets.
---
---
Amgen rides the trend of precision medicine and biologics, focusing on targeted therapies for complex diseases such as cancer and autoimmune disorders. The timing of acquiring Tularik aligned with growing industry emphasis on molecularly targeted drugs. Market forces favor companies that can innovate biologics with strong pipelines and global reach. Amgen’s integration of Tularik’s assets helped it maintain leadership in biopharma innovation, influencing the ecosystem by setting standards for strategic biotech acquisitions and pipeline expansion.
---
Going forward, Amgen is expected to continue leveraging acquisitions and internal R&D to expand its portfolio, especially in oncology and rare diseases. Trends such as personalized medicine, biologics, and gene therapies will shape its journey. The Tularik acquisition exemplifies Amgen’s strategy of integrating specialized biotech innovation to sustain growth and competitive advantage. Amgen’s influence will likely grow as it advances novel therapies addressing unmet medical needs globally, reinforcing its role as a biopharma pioneer.
